For the Inventor, By the Inventor

Enter assignee name

Mitsubishi Pharma Corporation

USPTO Granted Patents = 73

CIPO Patents = 4

EPO Patents = 2

Forward Citations = 721

Loading Chart...

Loading Chart...

194 inventors (with patents filed for the assignee):

Mourad Saady (19 out of 44 patents)

Alistair Lochead (19 out of 75 patents)

Philippe Yaiche (19 out of 43 patents)

4. Franck Slowinski (14 out of 17 patents)

5. Alain Nedelec (8 out of 18 patents)

6. Thierry Gallet (6 out of 13 patents)

7. Masayoshi Uehata (6 out of 11 patents)

8. Séverine Marguerie (6 out of 8 patents)

9. Kenji Chiba (5 out of 23 patents)

10. Kunitomo Adachi (4 out of 14 patents)

11. Takanobu Kuroita (4 out of 16 patents)

12. Adrien Tak Li (4 out of 14 patents)

13. Patrick Andre Lardenois (4 out of 21 patents)

14. Naoki Sugiyama (3 out of 44 patents)

15. Hiroyuki Satoh (3 out of 84 patents)

Core Competencies:

SIP Receptor Agonist

Neurodegenerative Diseases

Pyrimidine Derivatives

Monoclonal Antibody

GSK3 Inhibitors

Arterial Wall Disorder

Tumorigenesis Inhibitor

Visual Function Disorder

Hepatitis C Remedies

Cyclic Amide Derivatives

Protein Production

Therapeutic Agents

73 patents: Sort by Forward Citations

1. 8324283 - Solid pharmaceutical compositions comprising a SIP receptor agonist and a sugar alcohol (2012-12-04),

2. 8093256 - Use of 8-substituted-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives (2012-01-10),

3. 7781440 - [object Object] (2010-08-24),

4. 7659387 - Transgenic mammals introduced a Period 1 promoter that confers rhythmical expression (2010-02-09),

5. 7566720 - [object Object] (2009-07-28),

6. 7547705 - [object Object] (2009-06-16),

7. 7507746 - Enantiomer of tenatoprazole and the use thereof in therapy (2009-03-24),

8. 7507743 - Substituted 8'-pyridinyl-dihydrospiro-[cycloalkyl]-pyrimido[1,2-a] pyrimidin-6-one and 8′-pyrimidinyl-dihydrospiro-[cycloalkyl]-pyrimido[1,2-a] pyrimidin-6-one derivatives (2009-03-24),

9. 7465737 - [object Object] (2008-12-16),

10. 7462621 - Use of substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a] pyrimidin-5(1H)one derivatives as therapeutic agents (2008-12-09),

11. 7452897 - Use of substituted 2-(diaza-bicyclo-alkyl)-pyrimidone derivatives for the treatment of neurodegenerative diseases (2008-11-18),

12. 7429663 - 7-(Pyrimidin-4-yl)-Imidazo[1,2-a]Pyrimidin-5(1H)-ones as GSK3β inhibitors (2008-09-30),

13. 7427615 - 3-substituted-4-pyrimidone derivatives (2008-09-23),

14. 7396915 - Monoclonal antibody and gene encoding the same, hybridoma, pharmaceutical composition, and diagnostic reagent (2008-07-08),

15. 7393853 - [object Object] (2008-07-01),

Mitsubishi Pharma Corporation is a pharmaceutical company based in Japan. They focus on research, development, manufacturing, and marketing of innovative pharmaceutical products. With a commitment to improving the health and well-being of people, Mitsubishi Pharma strives to contribute to society through the creation of high-quality drugs and medical solutions.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

73 Patents

#129 in Osaka

#1,343 in Japan

#9,946 in the World

Mitsubishi Pharma Corporation

Forward Citations = 721

194 inventors:

Mourad Saady (19 out of 44 patents)

Alistair Lochead (19 out of 75 patents)

Philippe Yaiche (19 out of 43 patents)

4. Franck Slowinski (14 out of 17 patents)

5. Alain Nedelec (8 out of 18 patents)

Please report any incorrect information to support@idiyas.com

Loading…